慢性乙型肝炎患者抗病毒治疗前检测HBeAg的意义主要是什么?
What is the main significance of testing HBeAg before starting antiviral therapy in chronic hepatitis B?
HBeAg状态反映病毒复制的活跃程度并指导药物选择与疗程：HBeAg阳性者多处于免疫清除期、病毒载量高，经治后发生HBeAg血清学转换是重要治疗终点。HBeAg阴性者多为前C区或基本核心启动子变异株感染，往往需要更长期甚至无限期治疗。HBeAg状态及治疗后的应答情况还可辅助预判停药后复发概率。
HBeAg status reflects viral replication activity and guides drug selection and duration: HBeAg-positive patients are usually in the immune-active phase with high viral load, and HBeAg seroconversion on treatment is a key stopping point. HBeAg-negative infection typically involves precore or basal core promoter variants and requires longer, often indefinite, therapy. HBeAg status and the treatment response can also help predict the risk of relapse after discontinuation.
难度 进阶 · 适合 初中(12-15)
CC BY 4.0 · 来源待核验 · Source pending review
来源 · Source
出处备注：著录含书名，但缺版次 / 出版社 / 年份中的一部分，需编辑补全后才能做独立比对。
中华医学会肝病学分会《慢性乙型肝炎防治指南(2022年版)》 ; 另见: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, updated 2024; AASLD HBV Guidance 2023
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, updated 2024; AASLD HBV Guidance 2023 ; see also: 中华医学会肝病学分会《慢性乙型肝炎防治指南(2022年版)》
#肝胆胰疾病 #慢性乙型肝炎
慢性乙型肝炎为什么强调长期规范抗病毒治疗？擅自停药会有哪些风险？
Why does chronic hepatitis B require long-term standardized antiviral therapy, and what are the risks of stopping it on one's own?
恩替卡韦、替诺福韦等核苷（酸）类药物能持续抑制HBV DNA复制，使肝组织炎症坏死减轻、纤维化逆转或延缓。坚持规范的长期治疗可显著降低肝硬化失代偿与肝细胞癌的发生风险。擅自停药易导致病毒学反弹和转氨酶急剧升高，少数患者可发生致死性的肝炎急性发作，因此任何停药或换药都必须在专科医生监测下进行。
Nucleos(t)ide analogues such as entecavir and tenofovir sustainably suppress HBV DNA replication, easing necroinflammation and halting or reversing fibrosis. Adhering to a regular long-term regimen markedly lowers the risk of decompensated cirrhosis and hepatocellular carcinoma. Stopping abruptly invites virological rebound with sharp transaminase flares, and a few patients suffer fatal acute hepatitis, so any discontinuation or switch must proceed under specialist monitoring.
难度 进阶 · 适合 大众
CC BY 4.0 · 来源待核验 · Source pending review
来源 · Source
出处备注：著录含书名，但缺版次 / 出版社 / 年份中的一部分，需编辑补全后才能做独立比对。
中华医学会肝病学分会与感染病学分会《慢性乙型肝炎防治指南（2022年版）》
Guideline for the Prevention and Treatment of Chronic Hepatitis B (2022), Chinese Society of Hepatology and Chinese Society of Infectious Diseases
#乙型肝炎 #抗病毒治疗
HBeAg 阳性的慢性乙型肝炎患者接受核苷(酸)类似物治疗后,满足什么条件才可以考虑停药?停药后需要注意什么?
Under what conditions may HBeAg-positive patients with chronic hepatitis B consider stopping nucleos(t)ide analogue therapy, and what follow-up does stopping require?
按照现行国内外指南,HBeAg 阳性患者需实现 HBeAg 血清学转换(HBeAg消失、抗-HBe出现),并在转换后再巩固治疗至少3年,期间 ALT 持续正常、HBV DNA 持续检测不到,方可考虑停药。即使满足条件,停药后仍有相当比例患者病毒学复发甚至肝炎发作,必须每3个月左右监测肝功能、HBV DNA 和 HBeAg 状态。已存在肝硬化或显著肝纤维化的患者通常建议无限期服药,不适用停药策略。
Current national and international guidelines require HBeAg seroconversion (loss of HBeAg with emergence of anti-HBe) followed by at least three years of consolidation therapy during which ALT stays normal and HBV DNA remains undetectable before stopping is considered. Even when these conditions are met, a substantial share of patients relapse virologically or flare after withdrawal, so liver biochemistry, HBV DNA, and HBeAg status must be monitored roughly every three months. Patients with cirrhosis or significant fibrosis are generally kept on indefinite therapy and excluded from stopping strategies.
难度 进阶 · 适合 大众
CC BY 4.0 · 来源待核验 · Source pending review
来源 · Source
出处备注：著录含书名，但缺版次 / 出版社 / 年份中的一部分，需编辑补全后才能做独立比对。
中华医学会《慢性乙型肝炎防治指南(2022年版)》;EASL乙型肝炎感染处理临床实践指南,J Hepatol 2017;67:370-398
Chinese Society of Hepatology, Guidelines for prevention and treatment of chronic hepatitis B (2022 edition); EASL 2017 Clinical Practice Guidelines on hepatitis B, J Hepatol 2017;67:370-398
独立核验依据 · Independent verification: 核验依据 1 CROSSREF 标识 10.14218/jcth.2021.00209：Guidelines for Prev · 核验依据 3 Crossref DOI 10.1016/j.jhep.2017.03.021
#肝胆胰疾病 #慢性乙型肝炎